Just as SNSS Sunesis Pharmaceuticals (Vosaroxin AML)BNVI is on the verge of a great breahthrough. Both companies had a decline in pps due to financing and share dilution, both companies dipped under a $ as a result of that action and both companies had good PHASE II results. Now what happened with snss will happen to BNVI being a official start of PHASE III propelling pps 50 to 100% , check the status at clinical trials http://clinicaltrials.gov/ct2/show/NCT00906308?term=menerba&rank=1 the status will change into This study is currently recruiting participants when PHASE III starts(snss whent from 0.30$ to 0.65$. The only difference here is that SNSS was confronted with a possible reverse stock split because the 190 days to regain compliance with Nasdaq minimum price being 1$ was getting very close and they actually did the RS after pps soared on the PHASE III news. BNVI has no delistment issues like SNSS had because of the compliance period of 190 days. Possible delistment or RS is very far away and with a PPS at .82$ you can expect pps to go way over 1$ on the start of PHASE III news just in a matter of day's/weeks. Price target consensus is also much higher for BNVI than SNSS and the potential market for Menerba after FDA approval is HUGE. So with no RS or delistment issues, with good financials, with good PHASE II results, with the start of PHASE III just around the corner i see this a the best biotech deal in the market. Add the rumour of a possible partnership/buyout and this is a investment that can't possibly go wrong. Strong Buy IMO. Good luck. Holding 25K shares at .84 avg.